New drug combo aims to tackle hairy cell leukemia
NCT ID NCT06965114
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times
Summary
This study tests a combination of two drugs, tovorafenib and rituximab, in people with hairy cell leukemia that has returned or not responded to treatment, and also compares it to standard therapy for newly diagnosed patients. Tovorafenib blocks a protein that helps cancer grow, while rituximab helps the immune system attack cancer cells. The trial will check safety and how well the combination works in up to 84 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tovorafenib and rituximab
- What this could lead to
- If successful, this could offer a new targeted treatment option for hairy cell leukemia, potentially improving remission rates and reducing relapse.
- What could go wrong
- This is an early-phase trial with a small number of participants (84). The combination may cause side effects or not prove more effective than current standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NCI - Center for Cancer Research
RECRUITINGBethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial